News | Radiopharmaceuticals and Tracers | September 17, 2015

Novation Presents at National Meeting on Achieving Reliable Mo-99 Isotope Supplies

Event gathered international and domestic policy and technical experts to discuss progress on domestic production of valuable radioisotope without use of highly enriched uranium

Novation, Mo-99, NNSA 2015 meeting, reliable supplies, domestic production

September 17, 2015 — At the National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, Novation offered its support of efforts to encourage the adoption of processes to create a reliable domestic supply of non-highly enriched uranium (HEU) molybdenum-99 (Mo-99).

The meeting, hosted by Argonne National Laboratory and held in Boston Aug. 31-Sept. 3, brought together international and domestic policy and technical experts to present and discuss progress toward achieving the production of Mo-99 without the use of HEU.

When it comes to determining how the heart is functioning or whether cancer is present, doctors and patients rely on diagnostic tests using a radioactive medical-grade isotope made from Mo-99. Mo-99 is historically produced using HEU, an extremely dangerous substance used in nuclear weapons.

Leah Gannon, MBA, radiopharmaceutical portfolio executive for Novation, represented the company at the meeting. “Radiopharmaceuticals play a key role in the diagnosis of various disease states and have a complex and fragile supply chain. It was an honor to participate in the topical meeting to provide information around the barriers to entry in implementing non-HEU Mo-99 into the healthcare supply chain and propose an action plan to overcome those barriers,” said Gannon.

In her role at Novation, Gannon has worked on numerous imaging initiatives with a specific emphasis on radiopharmaceutical distribution and contrast media utilization. She also works with multi-disciplinary provider councils and task forces and is an active member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Association for Medical Imaging Management (AHRA).

Novation is committed to helping with the non-proliferation of HEU use in the production of radiopharmaceuticals as well as to helping the provider members it serves manage appropriate use of these medical isotopes. The company’s efforts include sharing best practices, providing active assistance with the development of successful programs, educating members on key medical imaging topics, and using institutional data to drive appropriate change in practice.

For more information: www.novationco.com

Related Content

A myocardial perfusion exam performed on the Siemens Biograph Vision PET-CT system.

A myocardial perfusion exam performed on the Siemens Biograph Vision PET-CT system.

Feature | Nuclear Imaging | June 15, 2018 | Dave Fornell, Editor
Nuclear imaging technology for both sing...
CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging | September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging | June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
Overlay Init